# Druggability Assessment: Epigenetic Clock Neurodegeneration Targets
## Overall Assessment Summary
**Most hypotheses have fundamental flaws, but I'll assess the top 2-3 for practical drug development feasibility.**
---
## Hypothesis 2: HDAC3-Selective Inhibition (Revised Confidence: 0.45)
### Druggability: MODERATE
**Target Class:** Zinc metalloenzyme - well-established druggable class
**Chemical Matter Status:** Advanced but limited selectivity
### Existing Compounds & Clinical Candidates:
- **RGFP966** (Repligen): Most selective HDAC3 inhibitor, ~40-fold selectivity over other HDACs
- **BG45** (University of Pennsylvania): Second-generation selective inhibitor
- **Entinostat (MS-275)**: Class I HDAC inhibitor with HDAC3 activity, FDA-approved for cancer
- **Clinical Status**: No HDAC3-selective compounds in neurodegeneration trials
### Competitive Landscape:
- **Established Players**: Novartis (panobinostat), Merck (vorinostat) - but focused on cancer
- **Emerging**: Regenacy Pharmaceuticals, Acetylon Pharmaceuticals (acquired by Celgene)
- **Academic Leaders**: University of Pennsylvania (Dr. Shelley Berger), Johns Hopkins
### Safety Concerns:
- **Black Box Warning**: Existing HDAC inhibitors carry warnings for thrombocytopenia, neutropenia
- **Metabolic Disruption**: HDAC3 regulates gluconeogenesis - risk of hypoglycemia
- **Cardiac Toxicity**: QT prolongation observed with pan-HDAC inhibitors
- **Fatigue/GI**: Universal side effects in current HDAC inhibitor trials
### Development Estimate:
- **Timeline**: 8-12 years to market
- **Cost**: $800M-1.2B (high due to CNS penetration requirements)
- **Key Challenges**: Achieving brain penetration while maintaining selectivity
---
## Hypothesis 3: SIRT6-NAD+ Enhancement (Revised Confidence: 0.35)
### Druggability: LOW-MODERATE
**Target Class:** NAD+-dependent deacetylase - challenging selectivity profile
**Chemical Matter Status:** NAD+ precursors available, SIRT6 activators limited
### Existing Compounds & Clinical Candidates:
**NAD+ Precursors (Market Ready):**
- **Nicotinamide Riboside**: ChromaDex (NIAGEN®) - $200M market
- **Nicotinamide Mononucleotide**: Multiple suppliers, regulatory uncertainty
- **Clinical Trials**:
- NCT04430517: NR in Alzheimer's (University of Delaware) - **NEGATIVE RESULTS**
- NCT03482167: NMN in aging (Washington University) - ongoing
**SIRT6 Activators (Research Stage):**
- **MDL-800** (laboratory compound): Modest 2-fold activation
- **UBCS039** (University of British Columbia): Limited data
- **No clinical candidates exist**
### Competitive Landscape:
- **ChromaDex**: Dominant in NAD+ precursor space, aggressive IP strategy
- **Elysium Health**: Consumer market focus with BASIS supplement
- **Academia**: MIT (Guarente), Harvard (Sinclair) - but controversial data
- **Big Pharma**: Limited interest due to mixed clinical results
### Safety Concerns:
- **NAD+ Precursors**: Generally well-tolerated but limited long-term data
- **Flushing/GI**: Common with high-dose niacin derivatives
- **Drug Interactions**: Potential with diabetes medications
- **Cancer Risk**: Theoretical concern with enhanced cellular energy
### Development Estimate:
- **Timeline**: 5-7 years for combination therapy
- **Cost**: $300-500M (leveraging existing NAD+ precursor safety data)
- **Key Challenge**: Proving brain target engagement for SIRT6
---
## Hypothesis 1: TET2 Overexpression (Revised Confidence: 0.35)
### Druggability: VERY LOW
**Target Class:** Enzymatic overexpression therapy - extremely challenging
**Chemical Matter Status:** No small molecule activators identified
### Existing Approaches:
- **Gene Therapy Vectors**:
- AAV-PHP.eB: Brain-penetrant capsid (Caltech/Roche collaboration)
- No TET2 overexpression programs in development
- **Protein Therapy**: Not feasible due to size and cofactor requirements
- **Small Molecule Activators**: None identified despite screening efforts
### Competitive Landscape:
- **Gene Therapy Leaders**: Roche/Genentech, Novartis, bluebird bio
- **CNS Gene Therapy**: Passage Bio (acquired by Roche), Voyager Therapeutics
- **Academic**: University of Pennsylvania (Wilson), Stanford (Porteus)
- **No direct competitors** for TET2 neurodegeneration
### Safety Concerns:
- **Immune Responses**: AAV immunogenicity, especially with repeat dosing
- **Genomic Instability**: Global demethylation risks chromosome instability
- **Off-Target Effects**: TET2 affects entire methylome, not specific sites
- **Manufacturing**: Complex vector production, $100K+ per dose
### Development Estimate:
- **Timeline**: 12-15 years (if feasible)
- **Cost**: $1.5-2B+ (gene therapy development costs)
- **Feasibility**: VERY LOW - recommend abandoning this approach
---
## Hypothesis 4: DNMT1 ASO Therapy (Revised Confidence: 0.25)
### Druggability: MODERATE (ASO platform proven)
**Target Class:** Antisense oligonucleotide - established platform
**Chemical Matter Status:** Multiple ASO chemistries available
### Existing Platform & Companies:
- **Ionis Pharmaceuticals**: Leader in ASO technology, multiple CNS programs
- **Roche/Genentech**: Partnership with Ionis, tominersen (Huntington's) - **FAILED Phase III**
- **Biogen**: Multiple ASO programs including nusinersen (Spinraza®) - $2B+ revenue
- **Wave Life Sciences**: Stereopure ASOs, mixed clinical results
### CNS ASO Programs:
- **Successful**: Nusinersen (SMA), approved 2016
- **Failed**: Tominersen (Huntington's), inotersen safety issues
- **Ongoing**: Multiple programs in ALS, Alzheimer's, Parkinson's
### Competitive Landscape:
- **Ionis**: Dominant with 40+ ASOs in development
- **Antisense Therapeutics**: Smaller player with ATL1102
- **Academic Collaborations**: Broad Institute, Cold Spring Harbor
### Safety Concerns:
- **Thrombocytopenia**: Class effect of ASOs, dose-limiting
- **Injection Site Reactions**: Intrathecal administration risks
- **CNS Inflammation**: Recent safety concerns with CNS ASOs
- **Essential Gene Target**: DNMT1 knockdown could cause cell death
### Development Estimate:
- **Timeline**: 10-12 years
- **Cost**: $1-1.5B (leveraging platform experience)
- **Risk**: HIGH due to essential nature of target
---
## RECOMMENDATION: Focus on HDAC3 Selective Inhibition
### Rationale:
1. **Most druggable target** with existing chemical matter
2. **Reasonable safety profile** compared to alternatives
3. **Established regulatory pathway** through cancer HDAC inhibitor experience
4. **Academic validation** through multiple independent labs
### Immediate Next Steps:
1. **License RGFP966** from Repligen or develop backup compound
2. **CNS penetration studies** - key technical hurdle
3. **Biomarker development** for target engagement
4. **IND-enabling toxicology** with focus on metabolic effects
### Estimated Investment Required:
- **Preclinical Development**: $50-75M over 3-4 years
- **Phase I Safety**: $25-40M over 18 months
- **Proof of Concept (Phase IIa)**: $75-100M over 2 years
- **Total to POC**: $150-215M over 5-6 years
### Key Success Metrics:
1. Brain penetration >10% of plasma levels
2. >50% HDAC3 inhibition in CSF biomarkers
3. No dose-limiting metabolic toxicity
4. Cognitive benefit signal in Phase IIa (n=150-200 patients)
**Bottom Line**: Only HDAC3 inhibition offers reasonable risk-adjusted probability of clinical success, but even this requires significant investment with moderate probability of failure.